Free Trial
→ Trump’s EO to send this $5 stock ripping higher…? (From Traders Agency) (Ad)tc pixel Free GNCA Stock Alerts

Genocea Biosciences (GNCA) Competitors

Genocea Biosciences logo
Compare

GNCA vs. CARM, BPTH, ARDS, SYRS, and TRVN

Should you buy Genocea Biosciences stock or one of its competitors? Genocea Biosciences's main competitors and comparable companies include Carisma Therapeutics (CARM), Bio-Path (BPTH), Aridis Pharmaceuticals (ARDS), Syros Pharmaceuticals (SYRS), and Trevena (TRVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Genocea Biosciences compare to Carisma Therapeutics?

Genocea Biosciences (NASDAQ:GNCA) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Genocea Biosciences has higher earnings, but lower revenue than Carisma Therapeutics. Genocea Biosciences is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Carisma Therapeutics$10.77M0.00-$60.48M$0.730.00

Genocea Biosciences has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Carisma Therapeutics -254.28%N/A -192.17%

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Carisma Therapeutics Neutral

Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.47, indicating that its stock price is 1,047% less volatile than the broader market.

Summary

Carisma Therapeutics beats Genocea Biosciences on 6 of the 10 factors compared between the two stocks.

How does Genocea Biosciences compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Bio-Path Neutral
Genocea Biosciences Neutral

Bio-Path has higher earnings, but lower revenue than Genocea Biosciences. Bio-Path is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-PathN/AN/A-$16.08M-$1.09N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bio-Path has a beta of -0.8, suggesting that its stock price is 180% less volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

Genocea Biosciences' return on equity of -182.88% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-PathN/A -2,842.40% -337.48%
Genocea Biosciences N/A -182.88%-62.76%

Summary

Genocea Biosciences beats Bio-Path on 6 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Aridis Pharmaceuticals?

Genocea Biosciences (NASDAQ:GNCA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Aridis Pharmaceuticals' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Aridis Pharmaceuticals N/A N/A N/A

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Aridis Pharmaceuticals has lower revenue, but higher earnings than Genocea Biosciences. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Aridis PharmaceuticalsN/AN/A-$30.37M-$0.02N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Aridis Pharmaceuticals Neutral

Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 55.49, indicating that its share price is 5,449% more volatile than the broader market.

Summary

Aridis Pharmaceuticals beats Genocea Biosciences on 7 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Syros Pharmaceuticals has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

Genocea Biosciences has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A

Genocea Biosciences' return on equity of -182.88% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Genocea Biosciences N/A -182.88%-62.76%

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Genocea Biosciences Neutral

91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Genocea Biosciences beats Syros Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Genocea Biosciences compare to Trevena?

Genocea Biosciences (NASDAQ:GNCA) and Trevena (NASDAQ:TRVN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Trevena's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Trevena N/A N/A -119.55%

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Trevena Neutral

Genocea Biosciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Trevena$443K0.00-$40.29M-$47.04N/A

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Trevena has a beta of -0.55, meaning that its share price is 155% less volatile than the broader market.

Summary

Genocea Biosciences beats Trevena on 5 of the 9 factors compared between the two stocks.

Get Genocea Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNCA vs. The Competition

Export
MetricGenocea BiosciencesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$6K$13.84B$7.86B$12.08B
Dividend YieldN/A2.56%2.46%4.50%
P/E Ratio0.0029.6834.5430.45
Price / SalesN/A7.558.915.88
Price / CashN/A15.7922.2322.80
Price / BookN/A4.964.403.79
Net Income-$33.20M$2.88B$3.51B$390.67M

Genocea Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
CARM
Carisma Therapeutics
N/A$0.00
+25.0%		N/A-99.1%$21K$10.77M0.0046
BPTH
Bio-Path
N/A$0.00
-40.0%		N/A-99.7%$16KN/AN/A10
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A-50.0%$11KN/AN/A37
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A-80.0%$11K$386KN/A68

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GNCA) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners
Trump’s Invisible Dollar Reset
Porter Stansberry believes President Trump could be about to trigger the biggest change to America's money in ...
Porter & Company | Sponsoredtc pixel
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a...
Traders Agency | Sponsoredtc pixel
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Uranium Mine Flood That Sparked a 2006 Price Surge Returns
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...
Digest Publishing | Sponsoredtc pixel
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...
Crypto 101 Media | Sponsoredtc pixel